A year ago at this time, a sale to another company was the last thing on the minds of senior executives at St. Francis Medical, one of the leading companies in dynamic stabilization. But interest by large spine companies put a halt to the company's plans to go public and led to an auction that was eventually won by Kyphon. Kyphon's acquisition of St. Francis Medical was one of the device industry's biggest deals in 2006--and just what everyone was waiting for.
by David Cassak
To many in the spine community, the news last December that Sunnyvale, CA-based Kyphon Inc. had entered into an agreement...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.
The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.
MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.
